Abstract

Vaccine strategies targeting the mucosal portal of entry may prevent HIV acquisition and systemic infection. Macrophages in cervicovaginal compartments are one of the first cell types to encounter virus upon vaginal exposure. Their activation can lead to recruitment of additional macrophages and CD4+ T-cells susceptible to viral infection. However, they are also critical in providing early protection against invading pathogens. Therefore, understanding their response to immunization is important for vaccine design. We immunized rhesus macaques twice mucosally with replicating adenovirus (Ad) SIV recombinants, followed by two intramuscular boosts with SIV gp120 protein. Macaques were subsequently challenged intravaginally with repeated low doses of SIVmac251. Using flow cytometry, we evaluated responses of cervicovaginal macrophages (CVM) and alveolar macrophages (AM) in bronchoalveolar lavage as initial immunization was to the upper respiratory tract. The frequency of CVM increased over the course of immunization; however, CCR5 expression significantly decreased. Significantly increased expression of the chemokines CCL3 (p < 0.01), CCL4, CCL5, and CXCL8 (p < 0.0001 for all) on CVM was seen post-1st Ad but their expression significantly decreased post-2nd boost. CD4+ T-cell frequency in the cervical mucosa remained unchanged. CVM FcγRIII expression was significantly increased at all time points post-immunization compared to naïve animals. FcγRIII expression post-2nd Ad positively correlated with the number of challenges needed for infection (r = 0.68; p = 0.0051). Vaccination increased AM FcγRIII expression which post-2nd boost correlated with antibody-dependent phagocytosis. Activation of AMs was evident by increased expression of CD40 and CD80 post-2nd Ad compared to naïve macaques. APRIL expression also significantly increased post-2nd Ad and correlated with B cell frequency in bronchoalveolar lavage (BAL) (r = 0.73; p = 0.0019) and total IgG in BAL-fluid (r = 0.53; p = 0.047). B cells cultured with SIV gp120-stimulated AM supernatant from vaccinated macaques exhibited significant increases in B cell activation markers CD38 and CD69 compared to B cells cultured alone or with AM supernatant from unvaccinated macaques. Overall, the vaccine regimen did not induce recruitment of susceptible cells to the vaginal mucosa but increased CVM FcγRIII expression which correlated with delayed SIV acquisition. Further, immunization induced expression of AM cytokines, including those associated with providing B cell help.

Highlights

  • Mucosal surfaces including the lungs, gut, sensory, and reproductive organs are permeable due to their physiological function

  • The epithelium lining the cervicovaginal compartment is the first line of defense against human immunodeficiency virus (HIV) entry during vaginal exposure as it provides a physical and immunological barrier

  • This can be beneficial as recognition of pathogenassociated molecular patterns (PAMPS) can lead to release of chemokines and cytokines that mediate inflammation and initiate innate immune responses [32]

Read more

Summary

Introduction

Mucosal surfaces including the lungs, gut, sensory, and reproductive organs are permeable due to their physiological function This makes the areas vulnerable to pathogens and mucosal immunity crucial for preventing invasion by infectious agents like human immunodeficiency virus (HIV). Once the endothelial barrier is crossed, a local increase of chemokine expression by the cervical epithelium leads to recruitment of CCR6+ plasmacytoid dendritic cells (pDC) and macrophages expressing chemokine receptors CCR5, CCR6, and CXCR2 [2, 3]. Recent studies in rhesus macaques have shown that CD4+ T cells, of the Th17-lineage, are primary target cells of simian immunodeficiency virus (SIV) [5] When infected, these cells form the small founder population that initially expands in the cervicovaginal mucosa leading to dissemination and systemic infection. Vaccines that can elicit strong mucosal immunity while preventing access to target cells at the site of exposure are crucial for successful protection against HIV/SIV

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.